Aug 2026· The Oncologist· Vol 31· 0 citations· 46 references
Medicine
TL;DR
Recurrent CCND1/FGF19-containing 11q13 amplification, TCR pathway alterations, TCR pathway alterations, and elevated metastatic TMB warrant evaluation as potential prognostic features in larger, independently validated cohorts with integrated HPV and immune profiling.
Abstract
Abstract Background Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited genomic data in Asian populations. Lymph node metastasis heavily dictates prognosis, yet molecular determinants of progression remain poorly understood. We aimed to characterize the genomic landscape and explore candidate prognostic genomic features using paired primary and metastatic PSCC tumors. Patients and Methods Targeted next-generation sequencing (437 cancer-related genes) was performed on primary tumors and matched lymph node metastases from 20 Chinese patients. Somatic alterations, intralesional heterogeneity, and tumor mutation burden (TMB) were analyzed and correlated with disease-free survival (DFS) and overall survival (OS). Results The most frequent primary tumor mutations included TP53 (45%) and TERT (40%). Notably, CCND1/FGF19 co-amplification (20% of cases) was associated with inferior DFS (P = .027) and showed a trend toward shorter OS (P = .050). Conversely, T-cell receptor (TCR) pathway alterations correlated with markedly improved survival. Comparing paired lesions revealed 59.8% shared alterations. Elevated TMB in metastases relative to matched primary tumors was significantly associated with poorer DFS (P = .008), while higher intralesional heterogeneity showed a trend toward worse OS. Conclusion Paired profiling revealed broadly conserved genomic features together with lesion-specific divergence in PSCC. Recurrent CCND1/FGF19-containing 11q13 amplification, TCR pathway alterations, and elevated metastatic TMB warrant evaluation as potential prognostic features in larger, independently validated cohorts with integrated HPV and immune profiling.
Muscle-invasive bladder cancer (MIBC) is a genomically complex disease with limited biomarkers for predicting patient outcomes. This study aimed to identify molecular correlates of overall survival in MIBC through comprehensive genomic profiling.
Tumor DNA from cystectomy specimens of 32 MIBC patients was...
C. Poyet, Ann Sophie Franzen, U. Bieri et al.· Journal of Cancer Research a...· 0 citations
Abstract Background Reliable prognostic biomarkers are urgently needed for operable esophageal squamous cell carcinoma (ESCC), as conventional histopathology often fails to detect minimal residual disease and accurately predict patient outcomes. Patients and Methods This study investigated the mutational patterns in ES...
Di Lu, Yu Tong, Chun-Hong He et al.· The Oncologist· 0 citations
While the genetic landscape of treatment-naïve head and neck squamous cell carcinoma (HNSCC) is well characterized, the molecular features of recurrent disease remain less defined. We investigated the genetic alterations in recurrent HNSCC and their associations with overall survival (OS), progression-free survival...
Olive Beyer, Andrey Loginov, D. Arons et al.· Scientific Reports· 0 citations
Primary tumors show an immunosuppressive phenotype, suggesting potential benefits from combining CTLA4 or IDO1 inhibitors with PD-1 blockade, and Liver metastases exhibit distinct immune features, supporting the need for site-specific precision therapies.
Ying Lu, T. Han, Li-Hui Wang et al.· Frontiers in Oncology· 0 citations
Introduction The risk of developing second primary cancers (SPC) after complete surgical resection of non-small cell lung cancer (NSCLC) has been estimated at 1-2% per patient-year. We investigated whether tumor genomic instability, assessed by tumor mutational burden (TMB), and host immune response, assessed by tumor-...
M. Gauthier, Maryam Karimi, S. Michiels et al.· Frontiers in Oncology· 0 citations
Background Pediatric testicular and ovarian germ cell tumors generally have favorable outcomes, but a subset of patients experience relapse, progression, or persistent disease. Conventional risk assessment is based primarily on stage, histology, primary site, serum tumor markers, and treatment response; the incremental...
Xiaoqi Xuan, Yue Yang, Yongle Li et al.· Human Mutation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.